Identifying appropriate biomarkers during periods of suppressed inflammatory cytokine expression could allow for timely IFN-β administration, which may help restore host defense mechanisms, prevent nosocomial infections, and potentially mitigate the progression of ARDS, thereby serving as a therapeutic intervention. Here, IFNB1 is linked to acute respiratory distress syndrome.